WILLIAM H. RASTETTER, PH.D. - Corporate Board Profile

NEUROCRINE BIOSCIENCES INC

Filing Date	Source Excerpt
2016-05-02	The Company 27s Audit Committee is comprised entirely of directors who meet the independence requirements set forth in Nasdaq Stock Market Rule9605(c)(2)(A). ... 2015 Director Compensation ... William H. Rastetter, Ph.D. ... $80,000 Fees Earned or Paid in Cash ... $842,622 Option Awards ... $922,622 Total
2017-04-21	William H. Rastetter, Ph.D. has served on the Board of Directors since February 2010 and as Chairman of the Board of Directors since May 2011. He is a member of the Science and Medical Technology Committee. Director Compensation Table shows total compensation of $568,790 for 2016.
2018-04-04	The nomination of William H. Rastetter, Ph.D. for election to the Companys Board of Directors is based on Dr. Rastetters scientific and technical expertise combined with his business experience in leading rapidly growing companies in the life science industry. The Companys Science and Medical Technology Committee consists of directors Gary A. Lyons, William H. Rastetter, Ph.D. and Alfred W. Sandrock, Jr. M.D., Ph.D. The following table sets forth the compensation paid by the Company for the fiscal year ended December 31, 2017 to the directors of the Company named below: William H. Rastetter, Ph.D.: Fees Earned or Paid in Cash $85,000, Option Awards $531,540, Total $616,540.
2019-04-17	The Company 2018 compensation for the Company 2018 to the directors of the Company named below: William H. Rastetter, Ph.D. 87,500 786,300 873,800
2020-04-09	William H. Rastetter, Ph.D. has served on the Board of Directors since February 2010 and as Chairman of the Board of Directors since May 2011. ... Dr. Rastetter serves as an advisor to SVB Leerink and Illumina Ventures. ... Dr. Rastetter has a Bachelor of Science degree in chemistry from MIT and received Master of Art and doctorate degrees in chemistry from Harvard University.
2021-04-09	William H. Rastetter, Ph.D. has served on the Board of Directors since February 2010 and as Chairman of the Board of Directors since May 2011. For 2020, directors who are not employees of the Company earned a $55,000 annual cash retainer. The Company provided the Chair of the Board, William H. Rastetter, an additional $30,000, making his total annual cash retainer $87,500. Additionally, for 2020, each non-employee director received a grant of a nonstatutory stock option to purchase 6,018 shares of the Companys common stock, representing an approximate value of $400,000 on the date of the 2020 Annual Meeting of Stockholders. The options granted to non-employee directors have exercise prices equal to the closing price of the Companys common stock on the date of the grant, are subject to a ten-year term and vest monthly over the one-year period following the date of grant. The following table sets forth the compensation earned for the fiscal year ended December 31, 2020 by the directors of the Company named below: William H. Rastetter, Ph.D. Fees Earned or Paid in Cash $88,271 Option Awards $400,030 Total $488,301.
2022-04-07	William H. Rastetter, Ph.D. has served on the Board of Directors since February 2010 and as Chairman of the Board of Directors since May 2011. ... For 2021, directors who are not employees of the Company earned a $60,000 annual cash retainer. The Company provided the Chair of the Board, William H. Rastetter, an additional $35,000, making his total annual cash retainer $95,000. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2021 by the directors of the Company named below: William H. Rastetter, Ph.D. $95,000 fees earned in cash and $400,003 option awards totaling $495,003.
2023-04-05	William H. Rastetter, Ph.D. has served on the Board of Directors since February 2010 and as Chairman of the Board of Directors since May 2011. Currently, he serves as the Chairman of the Board of Directors for Fate Therapeutics, a publicly traded company focused on cellular therapies, as well as for Daré Bioscience, Inc. (previously known as Cerulean Pharma Inc.), a publicly traded company focused on women’s healthcare. Dr. Rastetter also serves on the Board of Directors for Regulus Therapeutics Inc., a publicly traded company focused on RNA-based therapeutics. Dr. Rastetter previously served on the board of Grail, Inc., a private company developing deep sequencing approaches for disease diagnosis, with an initial focus on the early diagnosis of cancer. Dr. Rastetter serves as an advisor to Illumina Ventures, and is the Chairman of San Diego Squared, a nonprofit focused on STEM awareness and education for students in underserved communities. Dr. Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early 2013 and was Executive Chairman of Biogen Idec, Inc. from 2003 to 2005. Earlier, he served as Chairman and Chief Executive Officer of IDEC Pharmaceuticals Corporation until its merger with Biogen in 2003; he joined IDEC Corporation as its Chief Executive Officer at the company’s founding in 1986. From 1984 to 1986, Dr. Rastetter was Director of Corporate Ventures at Genentech, where from 1982 to 1984 he held scientific positions. He held a series of faculty positions including Associate Professor at the Massachusetts Institute of Technology (“MIT”) from 1975 to 1982. Dr. Rastetter has an S.B. degree in Chemistry from MIT and received M.A. and doctorate degrees in Chemistry from Harvard University. The fiscal 2022 compensation for the Company’s non-employee directors was recommended by the Compensation Committee to the Board following the review of a report from Aon, its independent compensation consultant during the first quarter of fiscal 2022, which contained an analysis of prevailing market practices regarding levels and types of non-employee director compensation, including the non-employee director compensation practices of our peer group, which is described in the “Compensation Discussion and Analysis” section of this proxy statement, and a comparative assessment of our non-employee director compensation to such peers and market practices. In fiscal 2022, the Compensation Committee also received a presentation from Aon about recent developments and best practices related to non-employee directors to inform its analysis of, and recommendations regarding, non-employee director compensation. For fiscal 2022, directors who are not employees of the Company earned a $60,000 annual cash retainer. The Company provided the Chair of the Board, William H. Rastetter, an additional $35,000, making his total annual cash retainer $95,000. Additionally, on the date of the 2022 Annual Meeting of Stockholders, each non-employee director received a nonstatutory stock option with an approximate grant date value of $400,000, covering the opportunity to purchase 9,724 shares of the Company's common stock. The options granted to non-employee directors have exercise prices equal to the closing price of the Company’s common stock on the date of the grant, are subject to a ten-year term and vest monthly over the one-year period following the date of grant.
2024-04-10	William H. Rastetter, Ph.D. has served on the Board of Directors since February 2010 and as Chairman of the Board of Directors since May 2011. ... Dr. Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early 2013 and was Executive Chairman of Biogen Idec, Inc. from 2003 to 2005. ... The Company’s Audit Committee is comprised entirely of directors who meet the independence requirements set forth in Nasdaq Stock Market Rule 5605(c)(2)(A). ... The members of the Audit Committee for 2023 were Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D., with Ms. Sharp serving as the Audit Committee Chair. ... The Company’s Compensation Committee consists of directors George J. Morrow, Richard F. Pops, and Shalini Sharp, with Mr. Pops serving as the Compensation Committee Chair. ... During 2023, the Company’s Nominating / Corporate Governance Committee consisted of directors Johanna Mercier, George J. Morrow, and Leslie V. Norwalk, and Stephen A. Sherwin, M.D., with Ms. Norwalk serving as the Nominating / Corporate Governance Committee Chair. ... In January 2024, the Board formed the Science and Medical Technology Committee, which provides oversight of significant scientific judgments relating to the Company’s research and development, including clinical development, activities, portfolio, and potential business development transactions. The Science and Medical Technology Committee consists of directors Stephen A. Sherwin, M.D., William H. Rastetter, Ph.D., Gary A. Lyons, and Richard F. Pops, with Dr. Sherwin serving as the Science and Medical Technology Committee Chair. ... Although Dr. Rastetter was not a member of any Board Committee in 2023, as Board Chair he attended most Board committee meetings. ... For fiscal 2023, directors who are not employees of the Company earned a $60,000 annual cash retainer. The Company provided the Chair of the Board, William H. Rastetter, an additional $35,000, making his total annual cash retainer $95,000. ... For fiscal 2023, on the date of the 2023 Annual Meeting of Stockholders, each continuing non-employee director received an annual equity award with an approximate grant date value of $400,000. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2023 by the directors of the Company named below: ... William H. Rastetter, Ph.D. $95,000 cash fees, $400,039 option awards, total $495,039.